M T Marino1, A Grilli1, C Baricordi1, M C Manara1, S Ventura1, R S Pinca1, M Bellenghi2, M Calvaruso3, G Mattia2, D Donati4, C Tripodo3, P Picci1, S Ferrari5, K Scotlandi6. 1. Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna. 2. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, Rome. 3. Hematology Unit with Bone Marrow Transplantation, University of Palermo, Palermo. 4. III Orthopaedic Clinic, Rizzoli Institute, Bologna. 5. Chemotherapy Section, Rizzoli Institute, Bologna, Italy. 6. Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna katia.scotlandi@ior.it.
Abstract
BACKGROUND: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. PATIENTS AND METHODS: Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9-241 months). Expression of miR-34a and of some of its targets (cyclin D1, bcl-2, SIRT1 and YY1) was evaluated by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same patients. RESULTS: High expression of miR-34a in localized tumors was significantly related to better event-free and overall survival (P = 0.004). Relevance of miR-34a was confirmed by using different calibrators (normal mesenchymal stem cells and different normal tissues). By multivariate Cox regression analysis, low miR-34a expression as well as nontotal necrosis and high levels of lactate dehydrogenase were all confirmed as independent risk factors associated with poor outcome. Expression of miR-34a was lower in metastases than in primary tumors. It inversely correlated with expression of cyclin D1 and Ki-67. CONCLUSIONS: By demonstrating its relationship with clinical outcome, we propose evaluation of miR-34a at diagnosis of EWS patients to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.
BACKGROUND: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWSpatients. PATIENTS AND METHODS: Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9-241 months). Expression of miR-34a and of some of its targets (cyclin D1, bcl-2, SIRT1 and YY1) was evaluated by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same patients. RESULTS: High expression of miR-34a in localized tumors was significantly related to better event-free and overall survival (P = 0.004). Relevance of miR-34a was confirmed by using different calibrators (normal mesenchymal stem cells and different normal tissues). By multivariate Cox regression analysis, low miR-34a expression as well as nontotal necrosis and high levels of lactate dehydrogenase were all confirmed as independent risk factors associated with poor outcome. Expression of miR-34a was lower in metastases than in primary tumors. It inversely correlated with expression of cyclin D1 and Ki-67. CONCLUSIONS: By demonstrating its relationship with clinical outcome, we propose evaluation of miR-34a at diagnosis of EWSpatients to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.
Authors: G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco Journal: Clin Transl Oncol Date: 2019-04-04 Impact factor: 3.405
Authors: Ji Hyung Hong; Kang San Roh; Sung-Suk Suh; Sukchan Lee; Sook Whan Sung; Jae Kil Park; Jae Ho Byun; Jin Hyoung Kang Journal: Tumour Biol Date: 2015-06-25
Authors: S Ventura; D N T Aryee; F Felicetti; A De Feo; C Mancarella; M C Manara; P Picci; M P Colombo; H Kovar; A Carè; K Scotlandi Journal: Oncogene Date: 2015-11-30 Impact factor: 9.867
Authors: Antonina Parafioriti; Caterina Bason; Elisabetta Armiraglio; Lucia Calciano; Primo Andrea Daolio; Martina Berardocco; Andrea Di Bernardo; Alessia Colosimo; Roberto Luksch; Anna C Berardi Journal: Int J Mol Sci Date: 2016-04-30 Impact factor: 5.923